A05AX07 · Alimentary tract and metabolism
Lyvdelzi (previously Seladelpar Gilead)
Indications
Lyvdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
Composition
- Active substance
- seladelpar lysine dihydrate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lyvdelzi (previously Seladelpar Gilead)
- Active substance
- seladelpar lysine dihydrate
- ATC code
- A05AX07
- Therapeutic area
- Liver Cirrhosis, Biliary
- Marketing authorisation holder
- Gilead Sciences Ireland Unlimited Company